Holen Sie sich die Stockscreener-App
0.9786
0.90%
0.0087
Handel nachbörslich:
.98
0.0014
+0.14%
Schlusskurs vom Vortag:
$0.9699
Offen:
$0.97
24-Stunden-Volumen:
36,132
Relative Volume:
0.65
Marktkapitalisierung:
$9.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.98M
KGV:
-0.3429
EPS:
-2.8535
Netto-Cashflow:
$-14.55M
1W Leistung:
-5.45%
1M Leistung:
-29.60%
6M Leistung:
-50.82%
1J Leistung:
-54.48%
1-Tages-Spanne:
$0.9507
$0.98
1-Wochen-Bereich:
$0.90
$1.08
52-Wochen-Spanne:
$0.90
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.9786 | 11.41M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oak Hill Bio, Research Alliance III (RACC) plan SPAC merger - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
Nuvation Bio sets Aug. 6 webcast on cancer treatment updates - Stock Titan
Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
63,969 shares bought by Tang Capital in Boundless Bio, Inc. (BOLD) - Stock Titan
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Q32 Bio (QTTB) shows Phase 2a alopecia areata responses with bempikibart - Stock Titan
[8-K] Q32 Bio Inc. Reports Material Event - Stock Titan
Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark - Stock Titan
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewswire Inc.
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) By Investing.com - Investing.com India
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Morningstar
Gossamer Bio (GOSS) Q1 2025 earnings summary - Quartr
BIO-key Regains Nasdaq Compliance; Trading to Resume July 8 - TradingView
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire
Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal - Stock Titan
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
Avai Bio (AVAI) notifies SEC of late FY2026 10-K, cites financial compilation - Stock Titan
Tang-linked entities report 11.3% stake in Boundless Bio (NASDAQ: BOLD) - Stock Titan
GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):